Somanath Shenoy, Ph.D.
Clinical and Administrative Pharmacy
|Ph.D.||NDRI, Indian Council of Agricultural Research||India||2000|
|B.S.||Mahatma Gandhi University||India||1994|
- Post-doctoral Experience
- Postdoctoral Fellow, Biological Sciences, Kent State University, Kent, OH, 2002-2003
Postdoctoral Fellow, Molecular Cardiology, Cleveland Clinic, Cleveland, OH, 2003-2007
- Honors and Awards
- • Young Investigator Award (2008) at the 12th Biennial Midwest Platelet Conference, University of Kentucky, Lexington, KY.
• New Investigator Travel Award (2007) at the 4th Annual Symposium of the American Heart Association Council on Basic Cardiovascular Sciences, Keystone, CO.
• Junior Investigator Award of Excellence (2007) at the Lerner Research Institute staff research retreat, Cleveland Clinic, for the second consecutive year.
• Junior Investigator Award of Excellence (2006) at the Lerner Research Institute staff research retreat, Cleveland Clinic.
• Irvine H. Page Award (2005) for the best publication at the Department of Molecular Cardiology, Cleveland Clinic.
• Innovator Award (2005) by the Cleveland Clinic for the invention of “Novel approach to control vascular maturation and permeability”.
- Research Interests
- Our long-term goal is to enable the development of new and innovative therapeutics for angiogenesis dependent clinical conditions and prostate cancer through better understanding of the molecular mechanisms regulating vascular permeability, angiogenesis, integrin activation, extracellular matrix remodeling and oncogenic transformation. Primary focus of our research is on Protein kinase B (Akt), a serine-threonine kinase, and its signaling partners on mediating these processes.
- Representative Publications
- Goc A, Chaudhary, M, Byzova, T.V. and Somanath, P.R. (2011) TGF-beta and bleomycin induced extracellular matrix secretion is mediated via Akt and mammalian target of rapamycin (mTOR). J Cell Physiol. 226(11):3004-13.
Kochuparambil, S.T, Al-Husein B, Goc A, Soliman, S, and Somanath, P.R. (2011). Anti-cancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced PSA expression. J Pharmacol. Exp. Ther. 336(2): 496-505.
Somanath, P.R., Vijai, J., Byzova, T.V. and Kandel, E.S. 2009. The role of PAK-1 in activation of MAP kinase cascade and oncogenic transformation by Akt. Oncogene, 28: 2365-2369.
Somanath, P.R., Kandel, E.S., Hay, N, Byzova, T.V. 2007. Akt1 signaling regulates integrin activation, matrix recognition and fibronectin matrix assembly. J. Biol. Chem. Aug 3 282(31): 22964-22976.
Chen, J. & Somanath, P.R (Co-first authors), Chen, WS, Hay, N, Byzova, T.V. 2005. Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nature Med. Nov.11 (11): 1188-1196.